A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

NCT01734382 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Juvenile Idiopathic Arthritis

Interventions

DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche